Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Friday. $70.43 million flowed into the stock on the tick-up and $123.04 million flowed out of the stock on the tick-down, for a money net flow of $52.61 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.05 for the day and closed at $34.82

PFE has been the topic of a number of recent research reports. Leerink Swann lowered their price objective on shares of Pfizer from $37.00 to $34.70 and set a “market perform” rating on the stock in a report on Monday, May 2nd. Sanford C. Bernstein set a $36.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, May 3rd. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $34.39 target price for the company. in a research note on Tuesday, May 3rd. Societe Generale set a $34.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, May 4th. Finally, Independent Research GmbH set a $37.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, May 4th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and an average price target of $38.82.

The firm has a market capitalization of $211.21 billion and a PE ratio of 30.87. The company has a 50-day moving average of $35.84 and a 200 day moving average of $33.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. During the same quarter in the previous year, the company posted $0.56 EPS. The firm had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. The firm’s revenue was up 10.9% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a dividend yield of 3.45%.

Several hedge funds and institutional investors have recently bought and sold shares of the company. CAM Group Holding A S increased its position in Pfizer by 111.2% in the fourth quarter. CAM Group Holding A S now owns 1,148,915 shares of the biopharmaceutical company’s stock valued at $37,087,000 after buying an additional 605,000 shares during the last quarter. SNS Financial Group LLC increased its position in Pfizer by 9.1% in the fourth quarter. SNS Financial Group LLC now owns 62,206 shares of the biopharmaceutical company’s stock valued at $2,008,000 after buying an additional 5,192 shares during the last quarter. Essex Financial Services Inc. increased its position in Pfizer by 51.8% in the fourth quarter. Essex Financial Services Inc. now owns 361,072 shares of the biopharmaceutical company’s stock valued at $11,655,000 after buying an additional 123,233 shares during the last quarter. Evanston Investments Inc. dba Evanston Advisors increased its position in Pfizer by 1.5% in the fourth quarter. Evanston Investments Inc. dba Evanston Advisors now owns 190,777 shares of the biopharmaceutical company’s stock valued at $6,158,000 after buying an additional 2,733 shares during the last quarter. Finally, Midas Management Corp increased its position in Pfizer by 5.5% in the fourth quarter. Midas Management Corp now owns 40,000 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 2,076 shares during the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.